POST Online Media Lite Edition



 

LoQus23 Therapeutics appoints Melanie Ivarsson as non-executive director

Christian Fernsby |
Cambridge, United Kingdom - LoQus23 Therapeutics, a biotech company, announced the appointment of Melanie Ivarsson, OBE, as non-executive director of the board.

Article continues below




Dr. Ivarsson is a highly accomplished leader in the life sciences sector with more than 20 years of experience at pharmaceutical companies including Eli Lilly, Pfizer, Shire and Takeda, working across all phases of clinical drug development.

Dr. Ivarsson's work has included treatments for rare diseases such as hereditary angioedema (Takhzyro, Cinryze, Firazyr) and lysosomal storage disorders including Gaucher disease (VPriv), Hunter's syndrome (Elaprase) and Metachromatic leukodystrophy.

She is currently Chief Development Officer at Moderna, where she oversees the delivery of all clinical development programmes across the company's portfolio and led clinical trials to develop one of the world's first Covid-19 vaccines.

 LATEST MOVES FROM United Kingdom 

Aston Martin appoints Amedeo Felisa as CEO
Titon Holdings appoints Alexandra French as chief executive officer
Pepco Group appoints Trevor Masters as permanent CEO
Victrex appoints Ian Melling as CFO
10x Banking appoints Virginia Gambale as non-executive director